X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/q32-bio-announces-closing-of-merger-with-homology-medicines-and-concurrent-private-placement-of-42-million-302098557.html
https://www.prnewswire.com/news-releases/q32-bio-announces-publication-of-preclinical-data-in-molecular-therapy-demonstrating-the-therapeutic-potential-of-tissue-targeted-complement-inhibitor-adx-097-for-complement-mediated-diseases-302066751.html
https://www.prnewswire.com/news-releases/q32-bio-regains-worldwide-rights-to-bempikibart-adx-914-from-amgen-301990062.html
https://www.prnewswire.com/news-releases/q32-bio-appoints-saul-fink-phd-as-chief-technology-officer-301966330.html
https://ir.horizontherapeutics.com/news-releases/news-release-details/q32-bio-and-horizon-therapeutics-plc-announce-dosing-first
https://www.prnewswire.com/news-releases/q32-bio-a-clinical-stage-biotechnology-company-focused-on-therapeutics-that-restore-immune-homeostasis-announces-ceo-transition-301627752.html
https://www.prnewswire.com/news-releases/q32-bio-and-horizon-therapeutics-announce-collaboration-in-autoimmune-diseases-301605204.html
https://www.prnewswire.com/news-releases/q32-bio-presents-new-preclinical-data-at-the-international-society-of-nephrology-frontiers-meeting-demonstrating-the-therapeutic-potential-of-adx-097-301573651.html
https://www.prnewswire.com/news-releases/q32-bio-initiates-first-in-human-phase-1-clinical-study-of-adx-097-for-the-treatment-of-complement-disorders-301555509.html
Market Place
Share 
